Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.69 |
| ▸ | LGALS1 | P09382 | 12/20 | 0.69 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1955667 | 1.00 | LGALS3 (0.69) | LGALS3LGALS1LGALS8 | |
| SCHEMBL15806280 | 0.87 | LGALS3 (0.55) | LGALS3LGALS1LGALS8 | |
| SCHEMBL12572816 | 0.87 | LGALS3 (0.55) | LGALS3LGALS1LGALS8 | |
| SCHEMBL1955106 | 0.87 | LGALS3 (0.83) | LGALS3LGALS1LGALS8 | |
| SCHEMBL1955104 | 0.87 | LGALS3 (0.83) | LGALS3LGALS1LGALS8 | |
| SCHEMBL17935486 | 0.79 | LGALS3 (0.74) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19630740 | 0.79 | LGALS3 (0.74) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19630739 | 0.79 | LGALS3 (0.74) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19630716 | 0.79 | LGALS3 (0.74) | LGALS3LGALS1LGALS8 | |
| SCHEMBL3284264 | 0.79 | LGALS3 (0.80) | LGALS3LGALS1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297174-B1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | GALECTO BIOTECH AB (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-20140171630-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | GALECTO BIOTECH AB (SE) | 2014-06-19 | — | — | US | disclosed |
| US-8697862-B2 | Synthesis of galactoside inhibitors | GALECTO BIOTECH AB (SE) | 2014-04-15 | — | — | US | disclosed |
| US-20140011765-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | GALECTO BIOTECH AB (SE) | 2014-01-09 | — | — | US | disclosed |
| US-20110130553-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | GALECTO BIOTECH AB (SE) | 2011-06-02 | — | — | US | disclosed |
| EP-2297174-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | Forskarpatent i Syd AB (SE) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009139719-A9 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | FORSKARPATENT I SYD AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009139719-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | FORSKARPATENT I SYD AB (SE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011765-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | ST6GAL1, GALNT10, ST3GAL3 | LGALS3 40/4885LGALS1 50/4885LGALS8 49/4885 |
| US-20110130553-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | ST6GAL1, GALNT10, ST3GAL3 | LGALS3 40/4885LGALS1 50/4885LGALS8 49/4885 |
| US-20140171630-A1 | NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS | ST6GAL1, GALNT10, ST3GAL3 | LGALS3 40/4885LGALS1 50/4885LGALS8 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.